Suppr超能文献

足板蛋白(d2-40)的免疫标记模式可区分基底细胞癌和毛发上皮瘤:49例临床病理及免疫组织化学研究

Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.

作者信息

Plaza Jose A, Ortega Pablo F, Bengana Chafik, Stockman David L, Suster Saul

机构信息

Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, USA.

出版信息

Am J Dermatopathol. 2010 Oct;32(7):683-7. doi: 10.1097/DAD.0b013e3181cf8fb4.

Abstract

When the morphologic distinction between basal cell carcinomas (BCCs) and tichoepitheliomas is unclear, it poses a rare diagnostic challenge as the commonly defined histologic criterion is insufficient for differentiating these two neoplasms from each other. Their distinction is clinically important because the risk of progressive disease in BCC can be problematic, and trichoepitheliomas misinterpreted as BCC burdens the patient with an inaccurate diagnosis and consequential inappropriate surgery. Podoplanin (D2-40) is a well-known lymphatic endothelial surface marker that has been postulated to be upregulated in the outer root sheath of hair follicles and cutaneous neoplasms, such as adnexal tumors, squamous cell carcinomas, etc. We studied the expression of D2-40 by immunohistochemistry to determine if this marker could reliably differentiate these neoplasms from each other. A total of 49 cutaneous tumors, including 22 cases of trichoepitheliomas and 27 cases of BCC were examined. Of the 27 cases of BCC, 18 cases were located in the head and neck area, 5 on upper extremities, and 4 on the back. Of the 22 cases of trichoepitheliomas, all were from the head and neck area. D2-40 expression was present in 21/22 cases of trichoepitheliomas; 11 cases were diffusely positive (50%), 10 cases were focally positive (45.5%), and 1 case was negative (4.5%). D2-40 expression was present in 6/27 cases of BCC; 2 cases were diffusely positive (7.4%), 4 cases were focally positive (14.8%), and 21 cases were negative (77.8%). In summary, D2-40 expression was only weakly and focally positive in BCC (22.2% of cases) and diffusely and weakly positive in trichoepitheliomas (95.5% of cases). The sensitivity and specificity of D2-40 immunoreactivity to separate trichoepitheliomas from BCCs was 95.5% and 77.8%, respectively. This data suggests that D2-40 expression could be a useful potential marker to distinguish BCCs from trichoepitheliomas, especially when there is a high index of histologic suspicion for either of these two tumors. Our results also suggest that BCC can show differentiation toward the outer root sheath of hair follicles.

摘要

当基底细胞癌(BCC)和毛发上皮瘤之间的形态学差异不明显时,由于通常定义的组织学标准不足以区分这两种肿瘤,这就带来了罕见的诊断挑战。它们的区分在临床上很重要,因为BCC中疾病进展的风险可能是个问题,而被误诊为BCC的毛发上皮瘤会给患者带来不准确的诊断以及随之而来的不适当手术。血小板源性生长因子受体配体(D2-40)是一种著名的淋巴管内皮表面标志物,据推测在毛囊外根鞘和皮肤肿瘤(如附属器肿瘤、鳞状细胞癌等)中上调。我们通过免疫组织化学研究了D2-40的表达,以确定该标志物是否能可靠地区分这些肿瘤。共检查了49例皮肤肿瘤,包括22例毛发上皮瘤和27例BCC。在27例BCC中,18例位于头颈部,5例位于上肢,4例位于背部。在22例毛发上皮瘤中,均来自头颈部。22例毛发上皮瘤中有21例存在D2-40表达;11例弥漫性阳性(50%),10例局灶性阳性(45.5%),1例阴性(4.5%)。27例BCC中有六例存在D2-40表达;2例弥漫性阳性(7.4%),4例局灶性阳性(14.8%),21例阴性(77.8%)。总之,D2-40表达在BCC中仅为弱阳性和局灶性阳性(22.2%的病例),在毛发上皮瘤中为弥漫性和弱阳性(95.5%的病例)。D2-40免疫反应性区分毛发上皮瘤和BCC的敏感性和特异性分别为95.5%和77.8%。该数据表明,D2-40表达可能是区分BCC和毛发上皮瘤的有用潜在标志物,尤其是当对这两种肿瘤中的任何一种存在高度组织学怀疑时。我们的结果还表明,BCC可表现出向毛囊外根鞘的分化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验